• Baird Medical received a Nasdaq deficiency notice dated November 2, 2026, for failing the USD 1 minimum bid price requirement.
• The company has 180 calendar days, until May 3, 2027, to regain compliance.
• Compliance requires ordinary shares to close at a bid price of at least USD 1 for 10 consecutive business days.
• Failure to comply could trigger delisting, though an additional 180-day grace period may be available subject to Nasdaq requirements.
• Ordinary shares continue trading uninterrupted on the Nasdaq Capital Market under ticker BDMD; the notice has no immediate listing effect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baird Medical Investment Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041601PRIMZONEFULLFEED9870478) on November 04, 2026, and is solely responsible for the information contained therein.